Clinical Trials Logo

Clinical Trial Summary

This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about 4 months. For about 3 months, they take BI 764198 or placebo as capsules once a day. Placebo capsules look like BI 764198 capsules but do not contain any medicine. Participants visit the study site about 10 times. You can participate in this study from your home. In this case a research nurse will visit you for the study visits. Kidney health is assessed based on the analysis of urine samples, which participants collect at home. At the end of the study, the results are compared between the different groups. During the study, the doctors also regularly check the general health of the participants.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05213624
Study type Interventional
Source Boehringer Ingelheim
Contact Boehringer Ingelheim
Phone 1-800-243-0127
Email clintriage.rdg@boehringer-ingelheim.com
Status Recruiting
Phase Phase 2
Start date March 10, 2022
Completion date February 21, 2025

See also
  Status Clinical Trial Phase
Completed NCT03907657 - Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Phase 2
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02238067 - Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis N/A
Completed NCT01194154 - A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA) Phase 2
Completed NCT02263833 - An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice N/A
Active, not recruiting NCT04078750 - PLATO - Medication Adherence in Transplant Recipients N/A
Recruiting NCT05490511 - Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus Phase 1
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Completed NCT03189212 - Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation N/A
Enrolling by invitation NCT05374291 - The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD Phase 3
Recruiting NCT05033054 - Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
Completed NCT05064267 - Hemostatic Profiles in Pediatric CKD
Not yet recruiting NCT06069518 - Continuous Glucose Monitoring in Patients With Diabetes on Peritoneal Dialysis
Not yet recruiting NCT03590067 - Oral Findings in a Group of Egyptian Pediatric Patients at Endstage Renal Disease
Recruiting NCT04014127 - Coronary Microvascular Dysfunction in Chronic Kidney Disease
Recruiting NCT04626323 - Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease Phase 2
Not yet recruiting NCT05774392 - An Observational Study of Patients With Chronic Kidney Disease
Recruiting NCT03615235 - APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Not yet recruiting NCT06343727 - A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) N/A
Completed NCT04515797 - QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir Phase 4